(A) MFI from EOMES, RUNX3, and T-bet in CD8 T cells pretreated with 50 μM of EX527 (SIRT1 inhibitor) overnight by flow cytometry (healthy subjects = 7; paired t test).
(B) MFI from EOMES and RUNX3 in TALL104 CD8 T cells pretreated with 1 μM of GSK126 (EZH2 inhibitor) overnight by flow cytometry (n = 4, 3 independent experiments; paired t test).
(C) MFI from RUNX3 in CD8 T cells in patients with SLE pretreated with 1 μM of GSK126 overnight by flow cytometry (SLE = 4; paired t test).
(D and E) Percentage of IFN-γ and GZMB in CD8CD38low or CD8CD38high T cells from healthy controls (D) and from patients with SLE (E) treated with 1 μM of GSK126 overnight by flow cytometry (healthy subjects = 5, shown in closed circle, SLE = 6, shown in opened circle; paired t test).
(F and G) Degranulation (%CD107a) of CD8CD38low or CD8CD38high T cells from healthy subjects (F) and from patients with SLE (G) treated with GSK126 overnight and stimulated with plate-coated CD3/CD28 antibodies for 5 h with GSK126 at the indicated concentration (n = 4, one-way ANOVA with multiple comparisons).